Drugs / INCB099318
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04272034 | Mar 2021 → Aug 2024 | anal carcinoma, cervical cancer, cutaneous neuroendocrine carcinoma, esophageal squamous cell carcinoma +8 | Incyte Corporation | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCB099318 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04272034 ↗ |
| Route | Oral | “administered orally” NCT04272034 ↗ |